Persistent Growth-promoting effects of vosoritide in children with achondroplasia are accompanied by improvements in physical and social aspects of health related quality of life

Publication of impact on health-related quality of life from 3 year data with vosoritide. These data suggest that after 3 years of treatment, vosoritide demonstrates a…

Read More

International Consensus Guidelines on the Implementation and Monitoring of Vosoritide Therapy in Individuals with Achondroplasia

Since the approval of vosoritide in 2021, a need was created for a treatment guideline for support clinicians. An international collaborative of leading experts and patient…

Read More

International Consensus Statement on the diagnosis, multidisciplinary management and lifelong care of individuals with achondroplasia

Achondroplasia is the most common skeletal dysplasia and is characterized by a variety of medical, functional and psychosocial challenges across the lifespan. There is variability in…

Read More

What is the Role for Pediatric Endocrinologists in the Management of Skeletal Dysplasias?

Despite the recognized expertise of pediatric endocrinologists, children with skeletal dysplasias have not been consistently managed by these physicians. Growth-altering treatments have broadened the role of…

Read More

Growth in achondroplasia including stature, weight, weight-for-height and head circumference from CLARITY: achondroplasia natural history study- a multicenter retrospective cohort study of achondroplasia in the US

Achondroplasia growth charts included in this article. Achondroplasia is the most common genetic skeletal disorder causing disproportionate short stature/dwarfism. Common additionalfeatures include spinal stenosis, midface retrusion,…

Read More

Constitutional Growth Delay

Constitutional Growth Delay and Familial Short Stature: A Guide for Families What is Short Stature? Doctors usually define short stature based on standard growth charts, rather…

Read More

Child with Suspected Short Stature

Primary Care provider guidelines for referral.

Read More

Cost-Conscious Growth-Promoting Treatment: When Discretion Is the Better Part of Value (HRP 2018)

A mini-review on cost-conscious growth-promoting treatment.

Read More

GH Deficiency, Idiopathic Short Stature, and IGF-I Deficiency Treatment Guidelines (HRP 2016)

PES Drugs and Therapeutics and Ethics committees present guidelines for Growth Hormone and Insulin-like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency.

Read More

Use of Aromatase Inhibitors in Children and Adolescents with Disorders of Growth and Adolescent Development (Pediatrics 2008)

A review of published data regarding the use of aromatase inhibitors in pediatrics.

Read More